Soligenix Receives EU Orphan Drug Designation for SGX945
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 15 hours ago
0mins
Should l Buy SNGX?
Source: Newsfilter
Soligenix Inc. shares rose by 18.33% in pre-market trading as the stock crossed above its 5-day SMA.
The significant price movement follows Soligenix receiving orphan drug designation from the European Commission for its drug SGX945, aimed at treating Behçet's Disease. This designation is expected to enhance the company's market competitiveness and comes after promising results from a Phase 2a clinical trial, where SGX945 showed a 40% improvement in oral ulcers compared to placebo. The orphan drug status will provide legal protection and market exclusivity, potentially increasing revenue prospects for Soligenix.
This development not only positions Soligenix favorably in the market but also highlights the company's commitment to addressing unmet medical needs. The orphan drug designation could lead to accelerated development and commercialization of SGX945, benefiting both the company and patients suffering from Behçet's Disease.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SNGX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SNGX
Wall Street analysts forecast SNGX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.200
Low
10.00
Averages
10.00
High
10.00
Current: 1.200
Low
10.00
Averages
10.00
High
10.00
About SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company, which is focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. The Company’s segments include Specialized Biotherapeutics, and Public Health Solutions. Its Specialized BioTherapeutics business segment is engaged in developing and focused on the commercialization of HyBryte (a proposed name of SGX301), a novel photodynamic therapy (PDT), utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). Its Public Health Solutions segment includes development programs for RiVax, its ricin toxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic-resistant and emerging infectious diseases and its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax, its vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, marking a significant advancement in addressing unmet medical needs and is expected to enhance the company's market competitiveness.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety, with the treatment group showing a 40% improvement in oral ulcers compared to the placebo group, laying a solid foundation for future market approval.
- Market Potential: With approximately 1 million people affected by Behçet's Disease globally, the successful development of SGX945 could provide new treatment options for these patients, potentially significantly increasing the company's revenue prospects.
- Intellectual Property Advantage: Soligenix holds a strong intellectual property position in its IDR technology platform, and the orphan drug and fast track designations for SGX945 will provide legal protection and market exclusivity for its future commercialization efforts.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, based on positive evaluations of its clinical trial results by the EMA, marking a significant advancement in addressing unmet medical needs.
- Market Exclusivity: Following the orphan drug designation, SGX945 will enjoy a 10-year period of market exclusivity in the EU, which will enhance the company's competitive edge and attract more investor interest in its product development.
- Clinical Trial Results: In a Phase 2a clinical trial involving 8 patients with Behçet's Disease, SGX945 demonstrated a 40% improvement in efficacy compared to a 37% improvement in the placebo group, indicating its potential in treating difficult-to-manage oral ulcers.
- Intellectual Property Protection: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide and related analogs, which will further strengthen its market position in the biopharmaceutical sector.
See More
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
- Clinical Trial Results: Soligenix is presenting positive findings for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) at the upcoming US Cutaneous Lymphoma Consortium Workshop, indicating significant clinical benefits in long-term treatment that could reshape CTCL therapy.
- Comparative Study Advantage: A study led by Dr. Brian Poligone shows that HyBryte™ demonstrates superior relative efficacy and tolerability compared to Valchlor® (mechlorethamine) in CTCL treatment, potentially offering patients a safer treatment option with reduced side effects.
- FDA Funding Support: The FDA awarded a $2.6 million Orphan Products Development grant to support the expanded treatment study of HyBryte™ in early-stage CTCL patients, further validating its effectiveness in home use settings and highlighting regulatory interest in the therapy.
- Follow-Up Research Plans: Soligenix is conducting a second Phase 3 trial, FLASH2, expected to enroll approximately 80 early-stage CTCL patients with an 18-week continuous treatment design, aimed at further validating HyBryte™'s efficacy and advancing its path to market approval.
See More
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
- Clinical Trial Results: Soligenix is set to present positive findings for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) at the upcoming US Cutaneous Lymphoma Consortium Workshop, indicating significant clinical benefits in long-term treatment, potentially offering patients a safer therapeutic option.
- Comparative Study Advantage: HyBryte™ demonstrated superior relative efficacy and tolerability compared to Valchlor® (mechlorethamine) in a study, particularly in treating plaque and patch lesions of CTCL, further solidifying its competitive position in the market.
- FDA Grant Support: The FDA awarded Soligenix a $2.6 million Orphan Products Development grant to support the expanded treatment study of HyBryte™ in early-stage CTCL patients, which will help accelerate clinical trial progress and enhance market recognition.
- Follow-up Research Plans: The second Phase 3 trial, FLASH2, has successfully achieved its first safety review milestone, with a blinded interim analysis expected to be completed in Q2 2026, paving the way for potential market approval for HyBryte™ if successful.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials
- Clinical Trial Results: Soligenix's summary of HyBryte™ clinical trials reveals significant efficacy in treating cutaneous T-cell lymphoma (CTCL), with 16% of patients achieving at least a 50% reduction in lesions at 8 weeks in the first phase study, compared to only 4% in the placebo group (p=0.04), laying a solid foundation for future market introduction.
- Safety Advantages: HyBryte™ utilizes a non-mutagenic mechanism and a safe visible light source, demonstrating better tolerability compared to traditional treatments like mechlorethamine, and showing excellent efficacy in treating thicker plaque lesions and difficult-to-treat variants, potentially positioning it as a first-line treatment option for CTCL patients.
- Future Research Plans: The ongoing FLASH2 Phase 3 study is expected to complete its interim analysis in Q2 2026, aiming to further validate the efficacy and safety of HyBryte™, and if successful, will support FDA and EMA marketing approvals, accelerating the product's commercialization process.
- Market Potential: With approximately 69,000 CTCL patients in the U.S. and Europe and about 7,000 new cases annually, the successful development of HyBryte™ could not only meet this unmet medical need but also generate substantial market revenue for Soligenix.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials for CTCL
- Clinical Trial Results: Soligenix announced that a summary of its HyBryte™ (synthetic hypericin) clinical trials for treating cutaneous T-cell lymphoma (CTCL) has been published in Expert Opinion on Investigational Drugs, highlighting its potential as a new first-line treatment option for early-stage CTCL.
- Significant Efficacy Data: In the first phase of the clinical trial, 16% of patients receiving HyBryte™ achieved at least a 50% reduction in lesions at 8 weeks, compared to only 4% in the placebo group, indicating a significant advantage in improving CTCL patient outcomes.
- Safety and Tolerability: HyBryte™ demonstrated good safety and tolerability, particularly when compared to traditional therapies, as its non-mutagenic mechanism and non-carcinogenic light source make it a safer alternative, reducing the risk of side effects for patients.
- Future Research Directions: Soligenix plans to complete an interim analysis of the FLASH2 study in Q2 2026, which will further validate the efficacy of HyBryte™, with expectations to accelerate patient recruitment and drive the drug's market approval process.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, marking a significant advancement in addressing unmet medical needs and is expected to enhance the company's market competitiveness.
- Clinical Trial Results: In the Phase 2a clinical trial, SGX945 demonstrated biological efficacy and safety, with the treatment group showing a 40% improvement in oral ulcers compared to the placebo group, laying a solid foundation for future market approval.
- Market Potential: With approximately 1 million people affected by Behçet's Disease globally, the successful development of SGX945 could provide new treatment options for these patients, potentially significantly increasing the company's revenue prospects.
- Intellectual Property Advantage: Soligenix holds a strong intellectual property position in its IDR technology platform, and the orphan drug and fast track designations for SGX945 will provide legal protection and market exclusivity for its future commercialization efforts.
See More
Soligenix Receives EU Orphan Drug Designation for SGX945
- Orphan Drug Designation: Soligenix's SGX945 has received orphan drug designation from the European Commission for treating Behçet's Disease, based on positive evaluations of its clinical trial results by the EMA, marking a significant advancement in addressing unmet medical needs.
- Market Exclusivity: Following the orphan drug designation, SGX945 will enjoy a 10-year period of market exclusivity in the EU, which will enhance the company's competitive edge and attract more investor interest in its product development.
- Clinical Trial Results: In a Phase 2a clinical trial involving 8 patients with Behçet's Disease, SGX945 demonstrated a 40% improvement in efficacy compared to a 37% improvement in the placebo group, indicating its potential in treating difficult-to-manage oral ulcers.
- Intellectual Property Protection: Soligenix holds a strong intellectual property position in its IDR technology platform, including patents for the composition of dusquetide and related analogs, which will further strengthen its market position in the biopharmaceutical sector.
See More
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
- Clinical Trial Results: Soligenix is presenting positive findings for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) at the upcoming US Cutaneous Lymphoma Consortium Workshop, indicating significant clinical benefits in long-term treatment that could reshape CTCL therapy.
- Comparative Study Advantage: A study led by Dr. Brian Poligone shows that HyBryte™ demonstrates superior relative efficacy and tolerability compared to Valchlor® (mechlorethamine) in CTCL treatment, potentially offering patients a safer treatment option with reduced side effects.
- FDA Funding Support: The FDA awarded a $2.6 million Orphan Products Development grant to support the expanded treatment study of HyBryte™ in early-stage CTCL patients, further validating its effectiveness in home use settings and highlighting regulatory interest in the therapy.
- Follow-Up Research Plans: Soligenix is conducting a second Phase 3 trial, FLASH2, expected to enroll approximately 80 early-stage CTCL patients with an 18-week continuous treatment design, aimed at further validating HyBryte™'s efficacy and advancing its path to market approval.
See More
Soligenix Highlights Positive Results for HyBryte™ in CTCL Treatment
- Clinical Trial Results: Soligenix is set to present positive findings for HyBryte™ in treating cutaneous T-cell lymphoma (CTCL) at the upcoming US Cutaneous Lymphoma Consortium Workshop, indicating significant clinical benefits in long-term treatment, potentially offering patients a safer therapeutic option.
- Comparative Study Advantage: HyBryte™ demonstrated superior relative efficacy and tolerability compared to Valchlor® (mechlorethamine) in a study, particularly in treating plaque and patch lesions of CTCL, further solidifying its competitive position in the market.
- FDA Grant Support: The FDA awarded Soligenix a $2.6 million Orphan Products Development grant to support the expanded treatment study of HyBryte™ in early-stage CTCL patients, which will help accelerate clinical trial progress and enhance market recognition.
- Follow-up Research Plans: The second Phase 3 trial, FLASH2, has successfully achieved its first safety review milestone, with a blinded interim analysis expected to be completed in Q2 2026, paving the way for potential market approval for HyBryte™ if successful.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials
- Clinical Trial Results: Soligenix's summary of HyBryte™ clinical trials reveals significant efficacy in treating cutaneous T-cell lymphoma (CTCL), with 16% of patients achieving at least a 50% reduction in lesions at 8 weeks in the first phase study, compared to only 4% in the placebo group (p=0.04), laying a solid foundation for future market introduction.
- Safety Advantages: HyBryte™ utilizes a non-mutagenic mechanism and a safe visible light source, demonstrating better tolerability compared to traditional treatments like mechlorethamine, and showing excellent efficacy in treating thicker plaque lesions and difficult-to-treat variants, potentially positioning it as a first-line treatment option for CTCL patients.
- Future Research Plans: The ongoing FLASH2 Phase 3 study is expected to complete its interim analysis in Q2 2026, aiming to further validate the efficacy and safety of HyBryte™, and if successful, will support FDA and EMA marketing approvals, accelerating the product's commercialization process.
- Market Potential: With approximately 69,000 CTCL patients in the U.S. and Europe and about 7,000 new cases annually, the successful development of HyBryte™ could not only meet this unmet medical need but also generate substantial market revenue for Soligenix.
See More
Soligenix Publishes Summary of HyBryte™ Clinical Trials for CTCL
- Clinical Trial Results: Soligenix announced that a summary of its HyBryte™ (synthetic hypericin) clinical trials for treating cutaneous T-cell lymphoma (CTCL) has been published in Expert Opinion on Investigational Drugs, highlighting its potential as a new first-line treatment option for early-stage CTCL.
- Significant Efficacy Data: In the first phase of the clinical trial, 16% of patients receiving HyBryte™ achieved at least a 50% reduction in lesions at 8 weeks, compared to only 4% in the placebo group, indicating a significant advantage in improving CTCL patient outcomes.
- Safety and Tolerability: HyBryte™ demonstrated good safety and tolerability, particularly when compared to traditional therapies, as its non-mutagenic mechanism and non-carcinogenic light source make it a safer alternative, reducing the risk of side effects for patients.
- Future Research Directions: Soligenix plans to complete an interim analysis of the FLASH2 study in Q2 2026, which will further validate the efficacy of HyBryte™, with expectations to accelerate patient recruitment and drive the drug's market approval process.
See More
